Irving Multi-PI Planning Grant

This service is provided by the Pilot and Collaborative Studies Resource (PCSR), the Columbia University Clinical Trials Office, and the Herbert Irving Comprehensive Cancer Center (HICCC).

Overview

The Irving Institute, in conjunction with the Columbia University Clinical Trials Office and the Herbert Irving Comprehensive Cancer Center (HICCC), is offering this one-year pilot award program providing funds ranging from $60,000 – 80,000 each for up to four (4) projects.  These pilot funds are intended to support the submission of multi-component biomedical research grants (e.g. SPORE, U54, P01, P50) and large multi-PI research grants (e.g. NCATS U01, MPI grants that require NIH preapproval). Priority will be given to projects proposing to apply for NCATS U01 and SPORE grants. It is expected that the Principal Investigator of those grants will be the pilot award applicant.

  • Duration: One year 
  • Award amount: $60,000 - 80,000
  • Number of awards: Up to four per year

See a list of current and past Irving Multi-PI planning grant award recipients here.

Eligibility 

For Principal Investigators (PIs):

  • Columbia University Irving Medical Center (CUIMC) faculty for non-cancer related projects.
  • CUIMC and Morningside faculty for cancer related projects.
  • Must be at the rank of Assistant Professor or above. Research Foundation for Mental Health (RFMH) faculty may apply as long as they have a full-time Columbia faculty appointment.
  • Awardees who previously received funding through this pilot award mechanism are not eligible unless the proposed project will support a new type of grant submission than the prior award.
  • Senior and executive faculty leadership in the Irving Institute and HICCC are eligible to apply.

For Projects:

  • All multi-component biomedical research grants and large multi-PI research grants by public and private funding agencies will be considered.
  • Scientific eligibility includes:
    • Translational and/or population research of any disease area; and/or
    • Basic, translational, clinical or population science research proposals in cancer.

Proposals should describe activities that support the submission of an eligible multi-component/multi-PI grant within 3 months of the end of the pilot 1-year award term.

Special Eligibility Considerations:

  • Proposals must include a description of the team and evidence of progress toward submission of an eligible multi-component/multi-PI grant (e.g. established External Advisory Board (EAB), established schedule of team meetings, discussions with a program director/official from the funding agency, etc.).
  • If the relevant eligible multi-component/multi-PI grant has previously been submitted and considered by an external funding agency, evidence of reasonable expectation of funding on resubmission, (e.g. a score and summary statement) and a plan to address the reviewers’ comments, are required.
  • We strongly encourage projects focusing on health equity.
  • We strongly encourage applications from underrepresented groups.

Deadlines

The application cycle for 2021 is now closed. Applications will be accepted again in Fall 2021.

Cite it, Submit it, Share it!

If your research has benefited from one or more Irving Institute resources, please remember to:

  • Cite our CTSA grant, UL1 TR001873, in any relevant publications, abstracts, chapters, and/or posters.
  • Submit your publications to PubMed Central (PMC) for compliance with the NIH Public Access Policy.
  • Share your research updates with us by sending an email to: irving.institute@columbia.edu

Contact

Kayla Zalcgendler
622 W 168th Street, 10th floor
New York, NY 10032
United States